Insight Health NVI-KT Regio Jan 2018 -Dez 2020 data on file; Basis verordnete Standardeinheiten Fertigarzneimittel; Umrechnung Standardeinheiten in DDD
Insight Health NVI-KT Regio Jan 2018 -Dez 2020 data on file; Basis Umsatz (AVP) in €
Insight Health NVI-KT Regio Jan-Dez 2020 data on file; Basis verordnete Packungen und AVP zum jeweiligen Lauer-Taxe Stand; Adalimumab nur 40 mg Einheiten, Preise Parallelimport nicht berücksichtigt
Biogen Q3 2022 Financial Results and Business Update. https://investors.biogen.com/static-files/7a6d8dcf-2646-471e-80ba-d6872a365dff; eingesehen am 08.02.2023
Q4 and Full Year 2021 Financial Results and Business Update. Biogen. February 3, 2022. https://investors.biogen.com/static-files/019bc8a4-527e-4565-a58b-91ef680630c1; eingesehen am 08.02.2023
Business Wire. Biogen and Samsung Bioepis Announce European Launch of IMRALDI™ (adalimumab), Solidifying Leadership in European Anti-TNF Market. https://www.businesswire.com/news/home/20181016006181/en/Biogen-and-Samsung-Bioepis-Announce-European-Launch-of-IMRALDI%E2%84%A2-adalimumab-Solidifying-Leadership-in-European-Anti-TNF-Market; Published 17 October 2018; eingesehen am 08.02.2023
Biogen Data on file